After listening to the conference call on the patent victory by management, I am in the mindset that the recent pop could be limited. I would prefer to exit the position and lock in the profit in this company. The company intends to pursue further litigation with a number of other companies. There could be more upside to this stock but I will refrain from adding to this position at this time. Hold recommendation.
Cara Therapeutics (CARA) has moved substantially since the sell off started in the mid 20's. The stock price is currently $12.20. The stock price has reached a neutral price point and will recommend a hold on the stock. There is a number of clinical updates expected and the stock has limited upside for the next 6 months. Hold recommendation.
Bluebird Bio has dropped since the sell recommendation by 16% and the current view on the stock price is neutral. More data will come out in December on their main drug pipeline and will continue to watch this stock closely for any updates on recommendations. Current recommendation a hold.
Hold on (DGLY)
Hold on (CARA)
Hold on (BLUE)
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.